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Detailed characterisation of raw LAMV samples and methods development for 
process analytics (for quantitative and qualitative assessments). 
Isolation of stable Form I and improvement of particle properties.
Solubility/MSZW determination of anti-solvent system for Lamivudine and 
evaluation of process feasibility (small scale development and assessment) 
Obtain stable Form I Lamivudine with improved particle properties through 
crystal habit modification 
Demonstration of crystallisation of modified stable Form I Lamivudine from batch 
to a continuous platform 
Modelling and feedback control/optimization of system 
Initial 
process 
evaluation
Batch 
process 
evaluation
Process 
translation
DMF/Acetone System 
Solubility Curve for Form I
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Water/Acetonitrile System 
Solubility Curve for Form I
• As with the solubility curve it can be seen from the 
supersaturation profiles that the addition of 
antisolvent drives the system into a significantly 
supersaturated state.
• With a maximum possible supersaturation of 3.5 
and a maximum predicted yield of 75%, this 
system is suitable for antisolvent crystallisation. 
• Might need to consider water activity for form 
control.
Conclusions 
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Models
End platform
*(MSMPR/COBC)
Rapid data collection
DoE
Kinetics
Automation
Machine learning
Experimental 
solubility
Induction 
times/*MSZW
Morphology
Miscibility
Viscosity 
ratios
AS nature
AS workflow
Platform selection
Process optimisation
Parameter estimation
System kinetics
Early Stage Process Workflow
Solvents Screening Novel Miniature Platform Development 
for Morphology Optimisation
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Miniaturised autonomous 
screening platform
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The feedback relation between the modules of the 
platform including temperature and flow control and 
the image processing.
LabVIEW front panel ensuring the automatic control and 
monitoring of the platform.
Feedback 
control
Automation  &
visualization
Future work 
• Increasing numbers of HIV/AIDS infections on yearly basis 
(2.1 million new cases in 2015, UNAIDS)
• Hepatitis B infections (257 million cases globally, WHO)
• Currently FDA-approved antiretroviral therapy for the 
prevention and treatment of both viral infections (FDA).
Why the considerations for 
Lamivudine?
To the best of our knowledge, no publication yet exists on 
continuous manufacturing of stable Lamivudine form 1. The 
key research question here is:
 Translate current batch crystallisation into a 
continuous process?
 Improve the downstream process-ability by modifying 
the particle properties?
 Develop miniaturise platforms for accelerated 
process development?
Key research considerations 
and interests
Form II
 Anhydrous
 Bi-pyramidal
 Thermodynamically 
favoured form
 Formed in anhydrous 
solvents
Form I
 0.2 Hydrate
 Needle-like
 Marketed API (Epivir®)
 Unstable under 
mechanical action
 Requires water activity 
of ~ 5 - 20% Recrystallised form I wet product 
from cooling crystallisation
• Only solutions prepared at starting points of 0.6 
and 0.4 solvent mass fractions can be driven 
into a supersaturated state by the addition of 
Acetonitrile.
• Highest achievable supersaturation: 1.5. 
Maximum projected yield: 32%
• This means that the yield of the isothermal anti-
solvent crystallisation in this system is 40%
lower than a cooling crystallisation
Chemical structure 
of Lamivudine
 Metastable zone width of the binary mixtures identified for the two 
solvents screening.
 A miniature platform was developed for morphology screening and 
incorporation of the feedback control to optimize the shape and size of 
Lamivudine crystals. 
 Screening of potential solvent pairs suitable for developing continuous antisolvent 
crystallisation.
 The developed novel platform will be applied for morphology screening and incorporation of 
the feedback control to optimize the shape and size of Lamivudine crystals.
Miniaturised parallel 
screening platform
15 vials with 
maximum of 8 mL 
working volume
Experimental Approach
Experimental set-up
*MSZW – Metastable zone width, *AS - Antisolvent
*MSMPR – Mixed-suspension, mixed-product removal
*COBC – Continuous oscillatory baffled crystalliser, 
*DoE – Design of experiment
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